Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection

Table 3 Clinical trials of therapeutic antibodies for COVID-19

Target & mAb drug	ClinicalTrials.gov identification	Type	Phase
*Anti-IL-6*
Clazakizumab	NCT04348500, 6 trials	Humanized rabbit IgG1 mAb	II
Siltuximab	NCT04329650, 3 trials	Chimeric IgGκ mAb	II/III
Olokizumab	NCT04452474, 2 trials	Humanized IgG4 mAb	II/III
*Anti-IL-6R*
Levilimab	NCT04397562	Human mAb	III
Sarilumab	NCT04661527, 9 trials	Human IgG1 mAb	I/II/III
Sirukumab	NCT04380961	Human IgG1κ mAb	II
Tocilizumab	NCT04372186, 56 trials	Humanized mouse IgG1 mAb	EUA
*Anti-IL-1β*
Canakinumab	NCT04362813, 5 trials	Human IgG1κ mAb	III
*Anti-TNF*
Infliximab	NCT04425538, 4 trials	Chimeric IgG1 mAb	II
Adalimumab	NCT04705844	Human mAb	III
*Anti-GM-CSF*
Lenzilumab	NCT04351152	Human IgG1 mAb	III
Otilimab	NCT04376684	Human IgG1 mAb	II
TJ003234	NCT04341116	Human IgG1 mAb	II/III
*Anti-GM-CSFR*
Gimsilumab	NCT04351243	Human IgG1 mAb	II
*Anti-GM-CSFR-α*
Mavrilimumab	NCT04447469, 5 trials	Human IgG4 mAb	II/III
*Anti-C5*
Eculizumab	NCT04346797, 4 trials	Humanized mouse IgG2/4κ mAb	II
*Anti-C5a*
Vilobelimab	NCT04333420	Chimeric IgG4 mAb	II/III
*Anti-C5aR*
Avdoralimab	NCT04371367, 2 trials	Human IgG1 mAb	II
*Anti-PD-1*
Nivolumab	NCT04356508, 3 trials	Human IgG4 mAb	II

ISSN: 1423-0127